1. Home
  2. SIGA vs BCYC Comparison

SIGA vs BCYC Comparison

Compare SIGA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SIGA Technologies Inc.

SIGA

SIGA Technologies Inc.

SELL

Current Price

$3.10

Market Cap

223.8M

Sector

Health Care

ML Signal

SELL

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

SELL

Current Price

$3.51

Market Cap

291.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SIGA
BCYC
Founded
1995
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.8M
291.8M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
SIGA
BCYC
Price
$3.10
$3.51
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
★ 583.0K
454.8K
Earning Date
11-05-2026
10-29-2026
Dividend Yield
★ 19.36%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.13
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$170.70
N/A
P/E Ratio
$23.85
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$3.33
52 Week High
$8.55
$9.08

Technical Indicators

Market Signals
Indicator
SIGA
BCYC
Relative Strength Index (RSI) 42.43 42.00
Support Level $2.92 $3.33
Resistance Level $3.32 $4.07
Average True Range (ATR) 0.15 0.19
MACD -0.03 0.02
Stochastic Oscillator 10.16 25.39

Price Performance

Historical Comparison
SIGA
BCYC

About SIGA SIGA Technologies Inc.

SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

Share on Social Networks: